Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720519 | 1.00 | ACE (0.60) | ACEPOLBTDP1L3MBTL1CHEK1 | |
| SCHEMBL13193021 | 0.89 | ACE (0.56) | ACEPOLBTDP1L3MBTL1CHEK1 | |
| SCHEMBL16879223 | 0.88 | ALDH1A1 (0.58) | ACEPOLBTDP1L3MBTL1CHEK1 | |
| SCHEMBL2080858 | 0.85 | ACE (0.59) | ACEPOLBTDP1L3MBTL1CHEK1 | |
| SCHEMBL7274646 | 0.85 | ACE (0.62) | ACEPOLBTDP1L3MBTL1 | |
| SCHEMBL29707284 | 0.85 | ACE (0.59) | ACEPOLBTDP1L3MBTL1CHEK1 | |
| SCHEMBL14067913 | 0.85 | ACE (0.59) | ACEPOLBTDP1L3MBTL1CHEK1 | |
| SCHEMBL66871 | 0.85 | ACE (0.59) | ACEPOLBTDP1L3MBTL1CHEK1 | |
| SCHEMBL7274651 | 0.85 | ACE (0.62) | ACEPOLBTDP1L3MBTL1 | |
| SCHEMBL66872 | 0.85 | ACE (0.59) | ACEPOLBTDP1L3MBTL1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543074-B1 | UV-CURABLE RESIN COMPOSITION FOR CLADDING OPTICAL FIBER | SSCP CO LTD (KR) | 2008-02-27 | — | — | EP | claimed |
| US-7046904-B2 | UV-curable resin composition for cladding optical fiber | SSCP CO., LTD. (KR) | 2006-05-16 | — | — | US | claimed |
| US-20060067638-A1 | Uv-curable resin composition for cladding optical fiber | LUVANTIX CO., LTD. (KR) | 2006-03-30 | — | — | US | claimed |
| EP-1543074-B1 | UV-CURABLE RESIN COMPOSITION FOR CLADDING OPTICAL FIBER | SSCP CO LTD (KR) | 2008-02-27 | — | — | EP | disclosed |
| US-7046904-B2 | UV-curable resin composition for cladding optical fiber | SSCP CO., LTD. (KR) | 2006-05-16 | — | — | US | disclosed |
| US-20060067638-A1 | Uv-curable resin composition for cladding optical fiber | LUVANTIX CO., LTD. (KR) | 2006-03-30 | — | — | US | disclosed |
| US-6730289-B2 | HAIR STYLING MIXTURE COMPRISING AN ACYLATED CARBAMATE GROUP MODIFIED POLYURETHANE AND ACCEPTABLE CARRIER OR DILUENT; NO DEPOSITS ON HAIR, WATER SOLUBLE | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20020176837-A1 | Cosmetic composition | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002058645-A1 | POLYURETHANES, COSMETIC COMPOSITIONS CONTAINING THEM AND METHOD OF PREPARATION | UNILEVER PLC (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020176837-A1 | Cosmetic composition | POLR1C, ALKBH5, HAT1 | ACE 4540/4885POLB 259/4885TDP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.